DekaBank Deutsche Girozentrale raised its position in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 2.3% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,901,908 shares of the pharmacy operator's stock after purchasing an additional 43,352 shares during the period. DekaBank Deutsche Girozentrale owned about 0.15% of CVS Health worth $126,847,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also bought and sold shares of the company. Hopwood Financial Services Inc. purchased a new stake in CVS Health during the 4th quarter valued at about $29,000. McIlrath & Eck LLC raised its holdings in shares of CVS Health by 32.6% during the fourth quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator's stock valued at $32,000 after acquiring an additional 174 shares during the last quarter. Park Square Financial Group LLC acquired a new position in shares of CVS Health during the fourth quarter valued at approximately $43,000. PARK CIRCLE Co increased its holdings in shares of CVS Health by 42.9% in the fourth quarter. PARK CIRCLE Co now owns 1,000 shares of the pharmacy operator's stock valued at $45,000 after purchasing an additional 300 shares during the last quarter. Finally, Strategic Investment Solutions Inc. IL increased its holdings in shares of CVS Health by 77.2% in the fourth quarter. Strategic Investment Solutions Inc. IL now owns 1,024 shares of the pharmacy operator's stock valued at $46,000 after purchasing an additional 446 shares during the last quarter. 80.66% of the stock is owned by institutional investors.
Analyst Ratings Changes
CVS has been the subject of several research analyst reports. UBS Group raised their price target on CVS Health from $67.00 to $71.00 and gave the stock a "neutral" rating in a research report on Friday, May 2nd. Cowen reissued a "buy" rating on shares of CVS Health in a report on Monday, May 5th. Wells Fargo & Company reaffirmed an "overweight" rating and set a $84.00 price objective (up from $76.00) on shares of CVS Health in a research note on Tuesday, May 6th. Wall Street Zen raised CVS Health from a "hold" rating to a "buy" rating in a research note on Friday, May 9th. Finally, Morgan Stanley reiterated an "overweight" rating on shares of CVS Health in a research report on Tuesday, April 15th. Two analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $75.06.
Read Our Latest Stock Analysis on CVS
Insider Buying and Selling at CVS Health
In related news, Director Guy P. Sansone bought 1,570 shares of CVS Health stock in a transaction that occurred on Thursday, June 5th. The stock was acquired at an average price of $63.70 per share, with a total value of $100,009.00. Following the acquisition, the director owned 12,007 shares of the company's stock, valued at approximately $764,845.90. This represents a 15.04% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.22% of the stock is owned by corporate insiders.
CVS Health Price Performance
Shares of CVS traded down $1.09 during mid-day trading on Friday, hitting $64.53. 2,312,076 shares of the company traded hands, compared to its average volume of 10,764,601. CVS Health Corporation has a one year low of $43.56 and a one year high of $72.51. The company has a current ratio of 0.82, a quick ratio of 0.63 and a debt-to-equity ratio of 0.77. The business has a 50-day moving average of $65.10 and a 200 day moving average of $62.08. The stock has a market capitalization of $81.63 billion, a price-to-earnings ratio of 15.40, a PEG ratio of 0.95 and a beta of 0.57.
CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.62 by $0.63. CVS Health had a net margin of 1.39% and a return on equity of 10.59%. The firm had revenue of $94.59 billion for the quarter, compared to analysts' expectations of $93.07 billion. During the same period last year, the firm earned $1.31 earnings per share. The business's revenue for the quarter was up 7.0% on a year-over-year basis. As a group, equities analysts expect that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.
CVS Health Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Tuesday, July 22nd will be paid a dividend of $0.665 per share. The ex-dividend date is Tuesday, July 22nd. This represents a $2.66 annualized dividend and a dividend yield of 4.12%. CVS Health's dividend payout ratio is presently 63.48%.
CVS Health Profile
(
Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
Featured Stories

Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.